Search research articles
Contact Us
Filters
Showing results (31-40 of 320) with videos related to
Page
of 32
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology
|
November 25, 2005
Mechanisms of statin-induced myopathy: a role for the ubiquitin-proteasome pathway?
M John Chapman, Alain Carrie
Pharmacological Reviews
|
September 14, 2006
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis
Anatol Kontush, M John Chapman
Current Atherosclerosis Reports
|
April 29, 2010
Lipidomics as a tool for the study of lipoprotein metabolism
Anatol Kontush, M John Chapman
Pharmacology & Therapeutics
|
June 30, 2022
Cholesterol crystals and atherosclerotic plaque instability: Therapeutic potential of Eicosapentaenoic acid
M John Chapman, R Preston Mason
Pharmacology & Therapeutics
|
January 25, 2008
Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy
M John Chapman, Andrei C Sposito
Arteriosclerosis, Thrombosis, and Vascular Biology
|
October 16, 2002
Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit
Andrei C Sposito, M John Chapman
Circulation
|
September 5, 2013
Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease
Bronwyn A Kingwell, M John Chapman
Journal of the American College of Cardiology
|
January 22, 2016
Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression After PCI: PRECISE-IVUS
Philippe Giral, Boris Hansel, John Chapman
The American Journal of Cardiology
|
July 17, 2007
The pi sign as an indicator of aberrant origin of obtuse marginal coronary artery
Alessandra Brofferio, Jamshid Shirani, John Chapman
Journal of the American College of Cardiology
|
October 26, 2019
Evolocumab Treatment of Hypercholesterolemia in OSLER-1: Enduring Efficacy, Tolerability, and Safety Over 5 Years
M John Chapman, Henry N Ginsberg
Page
of 32
Search research articles
Search
Showing results (31-40 of 320) with videos related to
Sort By:
Page
of 32
Arteriosclerosis, Thrombosis, and Vascular Biology
|
November 25, 2005
Mechanisms of statin-induced myopathy: a role for the ubiquitin-proteasome pathway?
M John Chapman, Alain Carrie
Pharmacological Reviews
|
September 14, 2006
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis
Anatol Kontush, M John Chapman
Current Atherosclerosis Reports
|
April 29, 2010
Lipidomics as a tool for the study of lipoprotein metabolism
Anatol Kontush, M John Chapman
Pharmacology & Therapeutics
|
June 30, 2022
Cholesterol crystals and atherosclerotic plaque instability: Therapeutic potential of Eicosapentaenoic acid
M John Chapman, R Preston Mason
Pharmacology & Therapeutics
|
January 25, 2008
Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy
M John Chapman, Andrei C Sposito
Arteriosclerosis, Thrombosis, and Vascular Biology
|
October 16, 2002
Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefit
Andrei C Sposito, M John Chapman
Circulation
|
September 5, 2013
Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease
Bronwyn A Kingwell, M John Chapman
Journal of the American College of Cardiology
|
January 22, 2016
Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression After PCI: PRECISE-IVUS
Philippe Giral, Boris Hansel, John Chapman
The American Journal of Cardiology
|
July 17, 2007
The pi sign as an indicator of aberrant origin of obtuse marginal coronary artery
Alessandra Brofferio, Jamshid Shirani, John Chapman
Journal of the American College of Cardiology
|
October 26, 2019
Evolocumab Treatment of Hypercholesterolemia in OSLER-1: Enduring Efficacy, Tolerability, and Safety Over 5 Years
M John Chapman, Henry N Ginsberg
Page
of 32